Aijie Hou

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Javed Butler, Ciaran J. McMullan, Kevin J. Anstrom et al. · The Lancet · 2025 · 64 citations · Full text

Medicine, Cardiology, Internal Medicine +12

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

Faı̈ez Zannad, Christopher M. O’Connor, Javed Butler et al. · The Lancet · 2025 · 32 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +17

The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure

Yang Gao, Changtai Xing, Wenjun Hao et al. · International Heart Journal · 2019 · 21 citations · Full text

Medicine, Cardiology, Pharmacology +17

<p>Incidence, Predictors, and Prognosis of Coronary Slow-Flow and No-Reflow Phenomenon in Patients with Chronic Total Occlusion Who Underwent Percutaneous Coronary Intervention</p>

Yong Wang, Hongwei Zhao, Chengfu Wang et al. · Therapeutics and Clinical Risk Management · 2020 · 17 citations · Full text

Medicine, Cardiology, Surgery +13

Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study

Yong Wang, Hongwei Zhao, Chengfu Wang et al. · BMC Cardiovascular Disorders · 2020 · 16 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17